A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or Together
A Trial to Investigate Single Dose Pharmacokinetics of NNC0148-0287sema in a Fixed Ratio Compared With Insulin 287 and Semaglutide Given Separately in Subjects With Type 2 Diabetes
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Neuss, Germany, 41460
- Novo Nordisk Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female, aged 18-64 years (both inclusive) at the time of signing informed consent
- Diagnosed with type 2 diabetes mellitus more than or equal to 180 days prior to the day of screening
- Body weight between 80.0 to 120.0 kg (both inclusive)
- Glycosylated haemoglobin (HbA1c) 6.0 to 8.5% (both inclusive)
- No current and no regular previous intake of insulin. Previous insulin treatment for short periods of time (a maximum of 14 days) is allowed, as well as insulin use during a previous period of gestational diabetes in the past (as declared by the subject or reported in the medical records)
- Stable daily dose(s) of the following anti-diabetic drug(s)/regimen within the past 90 days prior to the day of screening: a) Any metformin formulation (dose as documented in the subject medical record), b) One other oral antidiabetic drug (dose as documented in the subject medical record) is allowed, but not mandatory: Insulin secretagogue (sulphonylureas), dipeptidyl peptidase 4 (DPP-4) inhibitor and sodium glucose co-transporter 2 (SGLT2) inhibitor
Exclusion Criteria:
- Known or suspected hypersensitivity to trial products or related products
- Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive methods
- Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic event within the past 180 days) or hypoglycaemic unawareness as judged by the investigator or hospitalisation for diabetic ketoacidosis within the past 180 days prior to the day of screening
- Receipt of any investigational medicinal product within 90 days before screening
- History of severe allergies to drugs or foods or a history of severe anaphylactic reaction
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Semaglutide plus insulin 287
Participants will get a single dose of fixed-ratio combination of insulin 287 and semaglutide (NNC0148-0287sema (treatment C)).
|
Study staff will inject NNC0148-0287sema, 175unit (U)/0.5 mg in the morning after fasting under the skin of participants' thigh using a needle and a pen.
|
|
Experimental: Semaglutide alone
Participants will get a single dose of semaglutide (treatment B) alone.
|
Study staff will inject semaglutide, 0.5 mg alone in the morning after fasting under the skin of participants' thigh using a needle and a pen.
Other Names:
|
|
Experimental: Insulin 287 alone
Participants will get a single dose of insulin 287 (NNC0148-0287 (treatment A)) alone.
|
Study staff will inject insulin 287 (NNC0148-0287), 175U alone in the morning after fasting under the skin of participants' thigh using a needle and a pen.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
AUCI287, 0-tz, area under the serum insulin 287 concentration-time curve from 0 hours to last quantifiable observation after a single dose
Time Frame: 0-840 hours
|
Measured in pmol*h/L for insulin 287 following administration of a fixed ratio of NNC0148-0287sema and insulin 287.
|
0-840 hours
|
|
AUCSema,0-tz, area under the plasma semaglutide concentration-time curve from 0 hours to last quantifiable observation after a single dose
Time Frame: 0-840 hours
|
Measured in pmol*h/L for semaglutide following administration of a fixed ratio of NNC0148-0287sema and semaglutide.
|
0-840 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
AUCI287,0-∞ area under the serum insulin 287 concentration-time curve from 0 hours to infinity after a single dose
Time Frame: 0-840 hours
|
Measured in pmol*h/L for insulin 287 following administration of a fixed ratio of NNC0148-0287sema and insulin 287.
|
0-840 hours
|
|
Cmax, I287, maximum observed serum insulin 287 concentration after a single dose
Time Frame: 0-840 hours
|
Measured in pmol/L for insulin 287 following administration of a fixed ratio of NNC0148-0287sema and insulin 287.
|
0-840 hours
|
|
tmax, I287, time to maximum observed serum insulin 287 concentration after a single dose
Time Frame: 0-840 hours
|
Measured in hour (h) for insulin 287 following administration of a fixed ratio of NNC0148-0287sema and insulin 287.
|
0-840 hours
|
|
AUCSema,0-∞, area under the plasma semaglutide concentration-time curve from 0 hours to infinity after a single dose
Time Frame: 0-840 hours
|
Measured in pmol*h/L for semaglutide following administration of a fixed ratio of NNC0148-0287sema and semaglutide.
|
0-840 hours
|
|
Cmax,Sema, maximum observed plasma semaglutide concentration after a single dose
Time Frame: 0-840 hours
|
Measured in pmol/L for semaglutide following administration of a fixed ratio of NNC0148-0287sema and semaglutide.
|
0-840 hours
|
|
tmax,Sema, time to maximum observed plasma semaglutide concentration after a single dose
Time Frame: 0-840 hours
|
Measured in hour (h) for semaglutide following administration of a fixed ratio of NNC0148-0287sema and semaglutide.
|
0-840 hours
|
|
Number of treatment emergent adverse events
Time Frame: Day 1 (beginning of each period) to day 36 (end of each period)
|
Count of events.
|
Day 1 (beginning of each period) to day 36 (end of each period)
|
|
Number of hypoglycaemic episodes
Time Frame: Day 1 (beginning of each period) to day 36 (end of each period)
|
Count of episodes.
|
Day 1 (beginning of each period) to day 36 (end of each period)
|
|
Antibodies for insulin 287: Change in anti-insulin 287 binding antibody levels
Time Frame: Day -1 (pre-dose), Day 36 (end of period)
|
Measured as percentage B/T following administration of NNC0148 -0287sema and insulin 287.
|
Day -1 (pre-dose), Day 36 (end of period)
|
|
Antibodies for insulin 287: Occurrence of anti-insulin 287 binding antibodies
Time Frame: Day 36 (end of period)
|
Percentage of events (yes/no) following administration of NNC0148 -0287sema and insulin 287.
|
Day 36 (end of period)
|
|
Antibodies for insulin 287: Occurrence of anti-insulin 287 binding antibodies cross reacting to human insulin
Time Frame: Day 36 (end of period)
|
Percentage of events (yes/no) following administration of NNC0148 -0287sema and insulin 287.
|
Day 36 (end of period)
|
|
Antibodies for semaglutide: Change in anti-semaglutide binding antibody levels
Time Frame: Day -1 (pre-dose), Day 36 (end of period)
|
Measured as percentage B/T following administration of NNC0148 -0287sema
|
Day -1 (pre-dose), Day 36 (end of period)
|
|
Antibodies for semaglutide: Occurrence of anti-semaglutide binding antibodies
Time Frame: Day 36 (end of period)
|
Percentage of events (yes/no) following administration of NNC0148 -0287sema.
|
Day 36 (end of period)
|
|
Antibodies for semaglutide: Occurrence of anti-semaglutide binding antibodies cross reacting to endogenous glucagon-like peptide-1 (GLP-1)
Time Frame: Day 36 (end of period)
|
Percentage of events (yes/no) following administration of NNC0148 -0287sema.
|
Day 36 (end of period)
|
|
Binding antibodies and in vitro neutralising antibodies (semaglutide only): Anti-semaglutide binding antibody levels
Time Frame: Day 151 (follow-up/end-of-trial visit)
|
Measured as percentage B/T.
|
Day 151 (follow-up/end-of-trial visit)
|
|
Binding antibodies and in vitro neutralising antibodies (semaglutide only): Occurrence of anti-semaglutide binding antibodies cross reacting to endogenous GLP-1
Time Frame: Day 151 (follow-up/end-of-trial visit)
|
Percentage of events (yes/no).
|
Day 151 (follow-up/end-of-trial visit)
|
|
Binding antibodies and in vitro neutralising antibodies (semaglutide only): Anti-insulin 287 binding antibody levels
Time Frame: Day 151 (follow-up/end-of-trial visit)
|
Measured as percentage B/T.
|
Day 151 (follow-up/end-of-trial visit)
|
|
Binding antibodies and in vitro neutralising antibodies (semaglutide only): Occurrence of anti-insulin 287 binding antibodies cross reacting to human insulin
Time Frame: Day 151 (follow-up/end-of-trial visit)
|
Percentage of events (yes/no).
|
Day 151 (follow-up/end-of-trial visit)
|
|
Binding antibodies and in vitro neutralising antibodies (semaglutide only): Occurrence of anti-semaglutide neutralising antibodies
Time Frame: Day 151 (follow-up/end-of-trial visit)
|
Percentage of events (yes/no).
|
Day 151 (follow-up/end-of-trial visit)
|
|
Binding antibodies and in vitro neutralising antibodies (semaglutide only): Occurrence of anti-semaglutide neutralising antibodies cross reacting with endogenous GLP-1
Time Frame: Day 151 (follow-up/end-of-trial visit)
|
Percentage of events (yes/no).
|
Day 151 (follow-up/end-of-trial visit)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NN1535-4359
- U1111-1204-8233 (Other Identifier: World Health Organization (WHO))
- 2017-004538-27 (Registry Identifier: European Medicines Agency (EudraCT))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.